tiprankstipranks
Trending News
More News >
Fmc Corp. (FMC)
NYSE:FMC
Advertisement

FMC (FMC) AI Stock Analysis

Compare
1,479 Followers

Top Page

FMC

FMC

(NYSE:FMC)

Rating:58Neutral
Price Target:
$39.00
▲(4.59% Upside)
FMC's overall stock score reflects moderate financial health with significant challenges in revenue growth and cash flow management. Technical indicators suggest bearish momentum, and the high P/E ratio indicates potential overvaluation. Despite these concerns, the earnings call provided some positive insights, particularly regarding new product growth and regional performance in EMEA.
Positive Factors
Financial Performance
Updated FX rates increase revenue, which benefits the company's financial performance.
Market Expansion
The new direct-to-grower corn/soy sales channel in Brazil may boost volume recovery.
Negative Factors
Market Expectations
The 2026 EPS consensus is higher than the revised estimate, suggesting challenges in meeting market expectations.
Regulatory Impact
There is concern about the post-2026 setup due to the Rynaxypyr loss of exclusivity.
Trade Policy
A headwind from US tariffs on Canadian imports is expected to impact FMC's sales and earnings, with each 1% hit to US farm profits potentially cutting FMC sales by $3.8-5.8m.

FMC (FMC) vs. SPDR S&P 500 ETF (SPY)

FMC Business Overview & Revenue Model

Company DescriptionFMC Corporation (FMC) is a global agricultural sciences company that specializes in providing innovative solutions to enhance crop productivity and sustainability. Operating primarily in the agricultural sector, FMC focuses on the development and manufacture of crop protection products, including insecticides, herbicides, and fungicides, as well as plant nutrients and specialty chemicals. With a strong commitment to research and development, FMC leverages advanced technologies to address the needs of farmers and contribute to food security worldwide.
How the Company Makes MoneyFMC generates revenue through the sale of its crop protection products and solutions. The company's primary revenue streams include the sale of insecticides, herbicides, and fungicides, which are essential for protecting crops from pests and diseases. Additionally, FMC offers specialty products that enhance crop yield and quality, further contributing to its earnings. The company benefits from significant partnerships with agricultural distributors and retailers, allowing it to reach a broad customer base in various markets. Furthermore, FMC invests in research and development to innovate and expand its product portfolio, which helps to drive sales and maintain competitiveness in the agricultural industry.

FMC Key Performance Indicators (KPIs)

Any
Any
Revenue by Geography
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Chart InsightsFMC's revenue trends reveal strong growth in EMEA and Latin America, supported by higher herbicide sales and a successful growing season. However, North America and Asia face declines, exacerbated by destocking and competitive pressures in India, prompting a strategic divestment. Despite these regional challenges, FMC's focus on cost efficiencies and new product launches is expected to drive future growth, with a projected 14% increase in adjusted EBITDA for Q3 2025. Investors should watch for the impact of pricing pressures and FX headwinds on overall performance.
Data provided by:Main Street Data

FMC Earnings Call Summary

Earnings Call Date:Jul 30, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 04, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted several positive aspects, such as achieving higher-than-expected results for the second quarter, strong growth in the EMEA region, and successful debt management. However, it also pointed out challenges, particularly in the India market, where the company is divesting its commercial business due to competitive pressures and pricing declines. The outlook for new products remains strong, but pricing pressures and sales declines in North America are notable concerns.
Q2-2025 Updates
Positive Updates
Positive Second Quarter Results
Second quarter sales were 1% higher than the prior year, driven by volume growth of 6%. Adjusted EBITDA of $207 million was 2% higher than the prior year, and adjusted earnings per share of $0.69 was $0.10 higher than the prior year.
Strong Growth in EMEA Region
EMEA showed the strongest growth driven by higher volume of herbicides, diamide partner sales, and branded Cyazypyr.
Successful Debt Management
Sale of $750 million subordinated notes due in 2055, leverage neutral, with proceeds used to redeem May 2026 senior notes and pay down commercial paper, improving metrics with rating agencies.
Promising Outlook for New Products
Strong demand for new actives, fluindapyr and Isoflex, with registrations and sales expected in new markets. Introduction of Dodhylex active with meaningful sales expected to begin in 2027.
Negative Updates
Challenges in India Market
Decision to divest commercial business in India due to inability to enforce process patents and high working capital requirements in a challenging environment.
Pricing Pressures
Second quarter price was down 3%, with over half of the decline due to pricing adjustments made to diamide partners to account for lower manufacturing costs.
North America Sales Decline
North America sales declined 5% due to expected destocking in Canada and delayed purchases in the U.S. during the first quarter.
Company Guidance
During the Second Quarter 2025 Earnings Call for FMC Corporation, the company provided guidance that emphasized several key financial metrics and strategies. FMC anticipates revenue excluding India to be down 2% for the full year due to mid-single-digit price declines and flat to low single-digit foreign exchange headwinds. Volume growth is expected mainly in the second half, driven by a strong growth portfolio, including new active ingredients like fluindapyr and Isoflex. Adjusted EBITDA is projected to increase by 1% at the midpoint, with cost reductions offsetting price and FX headwinds. The company expects adjusted earnings per share to remain flat compared to the previous year. FMC also announced the divestment of its commercial business in India, citing challenges in the market, which will affect revenue guidance but not EBITDA or EPS. The company expects a strong performance in the second half, driven by growth strategies in Brazil and new product launches, and maintains its 2027 EBITDA target of $1.2 billion.

FMC Financial Statement Overview

Summary
FMC shows moderate financial health with declining revenue and profit margins, indicating challenges in growth and operational efficiency. The balance sheet is stable with manageable debt, but cash flow generation is concerning due to significant declines in free cash flow.
Income Statement
65
Positive
The TTM revenue of $4.12 billion shows a decline from the previous year's $4.49 billion, indicating a negative revenue growth rate. The gross profit margin is approximately 39.3%, showing strong profitability but with a slight decline from previous periods. The net profit margin stands at 8.1%, showing moderate profitability. However, EBIT and EBITDA margins have decreased, suggesting potential challenges in operational efficiency.
Balance Sheet
70
Positive
The debt-to-equity ratio is moderate at 0.22, indicating a balanced approach to leverage. The return on equity (ROE) is approximately 7.6%, which is relatively low, suggesting room for improvement in generating returns for shareholders. The equity ratio is around 37.1%, showing a stable capital structure with a healthy equity base.
Cash Flow
55
Neutral
The free cash flow has decreased significantly from $603.2 million to $243.3 million, indicating a substantial negative growth rate. The operating cash flow to net income ratio is 0.87, which is below optimal levels, suggesting challenges in cash generation relative to net income. The free cash flow to net income ratio is 0.73, showing limited free cash flow generation.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue4.13B4.25B4.49B5.80B5.05B4.64B
Gross Profit1.63B1.65B1.83B2.33B2.17B2.05B
EBITDA816.90M737.40M786.20M1.30B1.19B1.04B
Net Income99.20M339.90M1.32B736.50M739.60M552.40M
Balance Sheet
Total Assets12.30B11.65B11.93B11.17B10.58B10.19B
Cash, Cash Equivalents and Short-Term Investments438.20M357.30M302.40M572.00M516.80M568.90M
Total Debt4.16B3.50B4.11B3.27B3.17B3.27B
Total Liabilities7.87B7.14B7.49B7.77B7.53B7.20B
Stockholders Equity4.43B4.49B4.41B3.40B3.05B2.98B
Cash Flow
Free Cash Flow-7.30M603.20M-520.30M440.10M720.00M580.60M
Operating Cash Flow61.60M671.10M-386.40M582.40M820.10M647.80M
Investing Cash Flow265.20M263.60M-154.40M-266.40M-112.00M-169.30M
Financing Cash Flow-402.70M-870.10M331.50M-237.40M-747.90M-250.30M

FMC Technical Analysis

Technical Analysis Sentiment
Negative
Last Price37.29
Price Trends
50DMA
40.31
Negative
100DMA
39.80
Negative
200DMA
42.78
Negative
Market Momentum
MACD
-0.41
Positive
RSI
40.19
Neutral
STOCH
16.77
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FMC, the sentiment is Negative. The current price of 37.29 is below the 20-day moving average (MA) of 38.03, below the 50-day MA of 40.31, and below the 200-day MA of 42.78, indicating a bearish trend. The MACD of -0.41 indicates Positive momentum. The RSI at 40.19 is Neutral, neither overbought nor oversold. The STOCH value of 16.77 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FMC.

FMC Risk Analysis

FMC disclosed 37 risk factors in its most recent earnings report. FMC reported the most risks in the "Macro & Political" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

FMC Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
$14.16B11.4324.98%2.38%9.53%36.15%
66
Neutral
$10.55B11.287.80%2.64%-7.71%297.49%
64
Neutral
$8.08B22.016.24%2.93%-1.22%-14.31%
61
Neutral
$10.27B6.370.76%2.91%3.10%-36.03%
58
Neutral
$4.66B47.042.88%6.22%1.16%-92.85%
52
Neutral
$3.48B78.474.98%4.21%-2.05%
28
Underperform
$378.89M
42.75%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FMC
FMC
37.29
-22.41
-37.54%
CF
Cf Industries Holdings
84.18
7.48
9.75%
MOS
Mosaic Co
32.62
6.68
25.75%
SMG
Scotts Miracle-Gro Company
62.67
-3.45
-5.22%
ICL
Icl
6.09
2.03
50.00%
USBC
USBC
0.74
-10.12
-93.19%

FMC Corporate Events

Private Placements and Financing
FMC Completes $750 Million Subordinated Notes Sale
Neutral
May 28, 2025

On May 27, 2025, FMC Corporation completed the sale of $750 million in subordinated notes, which are set to mature in 2055. The notes, governed by a subordinated indenture, offer an 8.450% interest rate until 2030, after which the rate will reset every five years based on the U.S. Treasury Rate plus a spread, but not below 8.450%. The proceeds from this offering will be used to redeem existing senior notes and for general corporate purposes, impacting the company’s debt structure and financial obligations.

Private Placements and FinancingBusiness Operations and Strategy
FMC Announces $750M Subordinated Notes Issuance
Neutral
May 21, 2025

On May 19, 2025, FMC Corporation entered into an Underwriting Agreement with several underwriters to issue and sell $750 million of 8.450% Fixed-to-Fixed Reset Rate Subordinated Notes due 2055. The transaction is expected to close on May 27, 2025, with net proceeds of approximately $741 million anticipated after expenses. This move is part of FMC’s strategic financial operations, potentially impacting its financial structure and providing capital for future initiatives.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 19, 2025